Gut hormones and the regulation of energy homeostasis

[1]  T. Schwartz,et al.  GPR39 signaling is stimulated by zinc ions but not by obestatin. , 2007, Endocrinology.

[2]  P. Pfluger,et al.  Effects of obestatin on energy balance and growth hormone secretion in rodents. , 2007, Endocrinology.

[3]  P. Chelikani,et al.  Dose-dependent effects of peptide YY(3-36) on conditioned taste aversion in rats , 2006, Peptides.

[4]  Y. Taché,et al.  Lack of interaction between peripheral injection of CCK and obestatin in the regulation of gastric satiety signaling in rodents , 2006, Peptides.

[5]  A. Pfeiffer,et al.  Glucagon suppression of ghrelin secretion is exerted at hypothalamus-pituitary level. , 2006, The Journal of clinical endocrinology and metabolism.

[6]  Jimmy D Bell,et al.  Critical role for peptide YY in protein-mediated satiation and body-weight regulation. , 2006, Cell metabolism.

[7]  D. Cummings.  Ghrelin and the short- and long-term regulation of appetite and body weight , 2006, Physiology & Behavior.

[8]  E. Zorrilla,et al.  Vaccination against weight gain , 2006, Proceedings of the National Academy of Sciences.

[9]  J. Carvalheira,et al.  Circulating ghrelin concentrations are lowered by intracerebroventricular insulin , 2006, Diabetologia.

[10]  P. Pfluger,et al.  Ghrelin action in the brain controls adipocyte metabolism. , 2006, The Journal of clinical investigation.

[11]  C. Delporte,et al.  Role of endogenous ghrelin in the hyperphagia of mice with streptozotocin-induced diabetes. , 2006, Endocrinology.

[12]  M. Tschöp,et al.  Growth hormone secretagogue (ghrelin-) receptors--a complex drug target for the regulation of body weight. , 2006, CNS & neurological disorders drug targets.

[13]  S. Dey,et al.  Jekyll and Hyde : Two Faces of Cannabinoid Signaling in Male and Female Fertility , 2006 .

[14]  C. Cannon,et al.  Rimonabant: a cannabinoid receptor type 1 blocker for management of multiple cardiometabolic risk factors. , 2006, Journal of the American College of Cardiology.

[15]  P. Saha,et al.  Ablation of ghrelin improves the diabetic but not obese phenotype of ob/ob mice. , 2006, Cell metabolism.

[16]  R. Enriquez,et al.  Peptide YY ablation in mice leads to the development of hyperinsulinaemia and obesity , 2006, Diabetologia.

[17]  G. Frost,et al.  Oxyntomodulin increases energy expenditure in addition to decreasing energy intake in overweight and obese humans: a randomised controlled trial , 2006, International Journal of Obesity.

[18]  D. Drucker.  The biology of incretin hormones. , 2006, Cell metabolism.

[19]  W. Banks,et al.  Ghrelin controls hippocampal spine synapse density and memory performance , 2006, Nature Neuroscience.

[20]  S. Bloom,et al.  Progressive rise in gut hormone levels after Roux‐en‐Y gastric bypass suggests gut adaptation and explains altered satiety , 2006, The British journal of surgery.

[21]  J. Chan,et al.  Peptide YY Levels Are Elevated After Gastric Bypass Surgery , 2006, Obesity.

[22]  S. Bloom,et al.  The importance of acclimatisation and habituation to experimental conditions when investigating the anorectic effects of gastrointestinal hormones in the rat , 2006, International Journal of Obesity.

[23]  D. Keire,et al.  Daily, intermittent intravenous infusion of peptide YY(3-36) reduces daily food intake and adiposity in rats. , 2006, American journal of physiology. Regulatory, integrative and comparative physiology.

[24]  R. Batterham,et al.  Gut Hormone Profiles Following Bariatric Surgery Favor an Anorectic State, Facilitate Weight Loss, and Improve Metabolic Parameters , 2006, Annals of surgery.

[25]  K. Wynne,et al.  Attenuated peptide YY release in obese subjects is associated with reduced satiety. , 2006, Endocrinology.

[26]  Mohammad A Ghatei,et al.  Peptide YY3-36 and glucagon-like peptide-17-36 inhibit food intake additively. , 2005, Endocrinology.

[27]  H. Jang,et al.  Peptide YY is secreted after oral glucose administration in a gender-specific manner. , 2005, The Journal of clinical endocrinology and metabolism.

[28]  M. Kamm,et al.  Ghrelin enhances gastric emptying in diabetic gastroparesis: a double blind, placebo controlled, crossover study , 2005, Gut.

[29]  Jian V. Zhang,et al.  Obestatin, a Peptide Encoded by the Ghrelin Gene, Opposes Ghrelin's Effects on Food Intake , 2005, Science.

[30]  A. N. van den Pol,et al.  Peptide YY3-36 Inhibits Both Anorexigenic Proopiomelanocortin and Orexigenic Neuropeptide Y Neurons: Implications for Hypothalamic Regulation of Energy Homeostasis , 2005, The Journal of Neuroscience.

[31]  Christoph Beglinger,et al.  Effect of peptide YY3-36 on food intake in humans. , 2005, Gastroenterology.

[32]  D. Drucker.  Biologic actions and therapeutic potential of the proglucagon-derived peptides , 2005, Nature Clinical Practice Endocrinology &Metabolism.

[33]  J. Holst,et al.  A role for pancreatic polypeptide in the regulation of gastric emptying and short-term metabolic control. , 2005, The Journal of clinical endocrinology and metabolism.

[34]  D. Drucker,et al.  Peripheral exendin-4 and peptide YY(3-36) synergistically reduce food intake through different mechanisms in mice. , 2005, Endocrinology.

[35]  S. Bloom,et al.  Ghrelin does not stimulate food intake in patients with surgical procedures involving vagotomy. , 2005, The Journal of clinical endocrinology and metabolism.

[36]  Karim Meeran,et al.  Subcutaneous oxyntomodulin reduces body weight in overweight and obese subjects: a double-blind, randomized, controlled trial. , 2005, Diabetes.

[37]  V. Scott,et al.  Intravenous Peptide YY3‐36 and Y2 Receptor Antagonism in the Rat: Effects on Feeding Behaviour , 2005, Journal of neuroendocrinology.

[38]  G. Frost,et al.  Subcutaneous ghrelin enhances acute food intake in malnourished patients who receive maintenance peritoneal dialysis: a randomized, placebo-controlled trial. , 2005, Journal of the American Society of Nephrology : JASN.

[39]  Stephen R. Bloom,et al.  The inhibitory effects of peripheral administration of peptide YY3–36 and glucagon-like peptide-1 on food intake are attenuated by ablation of the vagal–brainstem–hypothalamic pathway , 2005, Brain Research.

[40]  K. Toshinai,et al.  The role of the vagal nerve in peripheral PYY3-36-induced feeding reduction in rats. , 2005, Endocrinology.

[41]  Dennis D. Kim,et al.  Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. , 2005, Diabetes care.

[42]  Dennis D. Kim,et al.  Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. , 2005, Diabetes care.

[43]  R. Cone.  Anatomy and regulation of the central melanocortin system , 2005, Nature Neuroscience.

[44]  C. Weyer,et al.  Adjunctive therapy with pramlintide lowers HbA1c without concomitant weight gain and increased risk of severe hypoglycemia in patients with type 1 diabetes approaching glycemic targets. , 2005, Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association.

[45]  S. Bloom,et al.  Ghrelin, peptide YY, glucose-dependent insulinotropic polypeptide, and hunger responses to a mixed meal in anorexic, obese, and control female adolescents. , 2005, The Journal of clinical endocrinology and metabolism.

[46]  K. Kangawa,et al.  Ghrelin: structure and function. , 2005, Physiological reviews.

[47]  J. Flier,et al.  The Gut and Energy Balance: Visceral Allies in the Obesity Wars , 2005, Science.

[48]  Stephen R. Bloom,et al.  Blockade of the neuropeptide Y Y2 receptor with the specific antagonist BIIE0246 attenuates the effect of endogenous and exogenous peptide YY(3–36) on food intake , 2005, Brain Research.

[49]  R. Cone,et al.  Peripheral administration of PYY(3-36) produces conditioned taste aversion in mice. , 2005, Cell metabolism.

[50]  T. Moran,et al.  Peptide YY(3-36) inhibits gastric emptying and produces acute reductions in food intake in rhesus monkeys. , 2005, American journal of physiology. Regulatory, integrative and comparative physiology.

[51]  P. Chelikani,et al.  Intravenous infusion of peptide YY(3-36) potently inhibits food intake in rats. , 2005, Endocrinology.

[52]  M. Bessler,et al.  Effects of Roux-en-Y gastric bypass surgery on fasting and postprandial concentrations of plasma ghrelin, peptide YY, and insulin. , 2005, The Journal of clinical endocrinology and metabolism.

[53]  S. O’Rahilly,et al.  Monogenic obesity in humans. , 2005, Annual review of medicine.

[54]  Susan E. Schonhoff,et al.  Effects of peptide YY[3-36] on short-term food intake in mice are not affected by prevailing plasma ghrelin levels. , 2004, Endocrinology.

[55]  Dennis D. Kim,et al.  Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. , 2004, Diabetes care.

[56]  A. Young,et al.  Effects of PYY[3–36] in rodent models of diabetes and obesity , 2004, International Journal of Obesity.

[57]  D. Drucker,et al.  Oxyntomodulin and glucagon-like peptide-1 differentially regulate murine food intake and energy expenditure. , 2004, Gastroenterology.

[58]  D. Allison,et al.  Physiology: Does gut hormone PYY3–36 decrease food intake in rodents? , 2004, Nature.

[59]  N. Martin,et al.  Pre-obese and obese agouti mice are sensitive to the anorectic effects of peptide YY3–36 but resistant to ghrelin , 2004, International Journal of Obesity.

[60]  A. Randich,et al.  Enhancement of feeding suppression by PYY3-36 in rats with area postrema ablations , 2004, Peptides.

[61]  Mohammad A Ghatei,et al.  Peripheral oxyntomodulin reduces food intake and body weight gain in rats. , 2004, Endocrinology.

[62]  G. Frost,et al.  Ghrelin increases energy intake in cancer patients with impaired appetite: acute, randomized, placebo-controlled trial. , 2004, The Journal of clinical endocrinology and metabolism.

[63]  R. Cone,et al.  Peptide YY3-36 inhibits food intake in mice through a melanocortin-4 receptor-independent mechanism. , 2004, Endocrinology.

[64]  A. G. Roseberry,et al.  Rapid Rewiring of Arcuate Nucleus Feeding Circuits by Leptin , 2004, Science.

[65]  J Dixon,et al.  Mice lacking pro-opiomelanocortin are sensitive to high-fat feeding but respond normally to the acute anorectic effects of peptide-YY(3-36). , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[66]  Abdulmajeed Al Abdukareem.  Randomized, placebo-controlled trial , 2004, Annals of Saudi medicine.

[67]  Mohammad A Ghatei,et al.  Oxyntomodulin suppresses appetite and reduces food intake in humans. , 2003, The Journal of clinical endocrinology and metabolism.

[68]  Mohammad A Ghatei,et al.  Inhibition of food intake in obese subjects by peptide YY3-36. , 2003, The New England journal of medicine.

[69]  G. Frost,et al.  Pancreatic polypeptide reduces appetite and food intake in humans. , 2003, The Journal of clinical endocrinology and metabolism.

[70]  K. Browning,et al.  Neuropeptide Y and Peptide YY Inhibit Excitatory Synaptic Transmission in the Rat Dorsal Motor Nucleus of the Vagus , 2003, The Journal of physiology.

[71]  M. Fujimiya,et al.  Characterization of the effects of pancreatic polypeptide in the regulation of energy balance. , 2003, Gastroenterology.

[72]  W. Tamborlane,et al.  The influence of insulin on circulating ghrelin. , 2003, American journal of physiology. Endocrinology and metabolism.

[73]  R. Freeman,et al.  Double-Blind , Placebo-Controlled , Crossover Study , 2003 .

[74]  Noboru Murakami,et al.  The role of the gastric afferent vagal nerve in ghrelin-induced feeding and growth hormone secretion in rats. , 2002, Gastroenterology.

[75]  Rachel L. Batterham,et al.  Gut hormone PYY3-36 physiologically inhibits food intake , 2002, Nature.

[76]  Mohammad A Ghatei,et al.  Repeated ICV administration of oxyntomodulin causes a greater reduction in body weight gain than in pair-fed rats. , 2002, American journal of physiology. Endocrinology and metabolism.

[77]  W. Weiss.  Pharmacotherapy for obesity. , 2002, The New England journal of medicine.

[78]  Yuichiro Yamada,et al.  Inhibition of gastric inhibitory polypeptide signaling prevents obesity , 2002, Nature Medicine.

[79]  C. Weyer,et al.  A randomized study and open-label extension evaluating the long-term efficacy of pramlintide as an adjunct to insulin therapy in type 1 diabetes. , 2002, Diabetes care.

[80]  T. Moran,et al.  Actions of CCK in the controls of food intake and body weight: Lessons from the CCK-A receptor deficient OLETF rat , 2002, Neuropeptides.

[81]  A. Asakawa,et al.  Roles of pancreatic polypeptide in regulation of food intake , 2002, Peptides.

[82]  D. Smith,et al.  Oxyntomodulin inhibits food intake in the rat. , 2001, Endocrinology.

[83]  A. Astrup,et al.  Effect of sibutramine on weight maintenance after weight loss: a randomised trial , 2000, The Lancet.

[84]  M. Tschöp,et al.  Ghrelin induces adiposity in rodents , 2000, Nature.

[85]  T. Moran,et al.  Cholecystokinin and satiety: current perspectives. , 2000, Nutrition.

[86]  S. Woods,et al.  Central nervous system control of food intake , 2000, Nature.

[87]  J. Miyazaki,et al.  Glucose intolerance caused by a defect in the entero-insular axis: a study in gastric inhibitory polypeptide receptor knockout mice. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[88]  J. Blundell,et al.  Untangling the effects of hunger, anxiety, and nausea on energy intake during intravenous cholecystokinin octapeptide (CCK-8) infusion , 1998, Physiology & Behavior.

[89]  C. H. Chen,et al.  Peptide YY and the Y2 agonist PYY-(13-36) inhibit neurons of the dorsal motor nucleus of the vagus. , 1997, The American journal of physiology.

[90]  D. Mcfadden,et al.  The effect of SMS 201-995 on meal and CCK-stimulated peptide YY release. , 1991, The Journal of surgical research.

[91]  M. Greenwood,et al.  Infusion of cholecystokinin between meals into free-feeding rats fails to prolong the intermeal interval , 1987, Physiology & Behavior.

[92]  T. Adrian,et al.  Peptide YY abnormalities in gastrointestinal diseases. , 1986, Gastroenterology.

[93]  S. Woods,et al.  Cholecystokinin persistently suppresses meal size but not food intake in free-feeding rats. , 1984, The American journal of physiology.

[94]  R. Modigliani,et al.  Gut hormones in inflammatory bowel disease. , 1983, Scandinavian journal of gastroenterology.

[95]  J. Crawley,et al.  Rapid development of tolerance to the behavioural actions of cholecystokinin , 1983, Nature.

[96]  T. Adrian,et al.  Effect of partial ileal bypass on the gut hormone responses to food in man. , 1983, Digestion.

[97]  M. Gregor,et al.  Gut hormones in tropical malabsorption. , 1979, British medical journal.

[98]  H. Kowarzyk.  Structure and Function. , 1910, Nature.